Ani Pharmaceuticals Inc ANIP
We take great care to ensure that the data presented and summarized in this overview for ANI PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANIP
View all-
Black Rock Inc. New York, NY2.53MShares$162 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.31MShares$83.9 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY959KShares$61.5 Million2.26% of portfolio
-
Deep Track Capital, LP Greenwich, CT822KShares$52.8 Million1.88% of portfolio
-
Dimensional Fund Advisors LP Austin, TX609KShares$39.1 Million0.01% of portfolio
-
State Street Corp Boston, MA575KShares$36.9 Million0.0% of portfolio
-
William Blair Investment Management, LLC Chicago, IL490KShares$31.5 Million0.09% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX402KShares$25.8 Million1.83% of portfolio
-
Global Alpha Capital Management Ltd.391KShares$25.1 Million2.01% of portfolio
-
Geode Capital Management, LLC Boston, MA339KShares$21.8 Million0.0% of portfolio
Latest Institutional Activity in ANIP
Top Purchases
Top Sells
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Insider Transactions at ANIP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
20,000
-2.85%
|
$1,160,000
$58.9 P/Share
|
|
Jun 20
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
11,447
-1.6%
|
$675,373
$59.86 P/Share
|
|
Jun 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,607
-1.46%
|
$636,420
$60.76 P/Share
|
|
Jun 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
7,946
-1.08%
|
$484,706
$61.41 P/Share
|
|
Jun 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$15,750
$63.8 P/Share
|
|
Jun 07
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
11,087
-8.6%
|
$742,829
$67.7 P/Share
|
|
Jun 07
2024
|
James G. Marken SVP OPS & PROD DEV |
BUY
Exercise of conversion of derivative security
|
Direct |
12,550
+4.74%
|
$665,150
$53.29 P/Share
|
|
Jun 05
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
2,985
-3.72%
|
$199,995
$67.0 P/Share
|
|
Jun 04
2024
|
Stephen P. Carey SVP & CFO |
SELL
Open market or private sale
|
Direct |
5,000
-2.99%
|
$315,000
$63.58 P/Share
|
|
Jun 03
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-8.58%
|
$1,280,000
$64.41 P/Share
|
|
May 21
2024
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+9.8%
|
-
|
|
May 21
2024
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+5.57%
|
-
|
|
May 21
2024
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+12.44%
|
-
|
|
May 21
2024
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+16.31%
|
-
|
|
May 21
2024
|
Matthew J Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+26.89%
|
-
|
|
May 21
2024
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+7.88%
|
-
|
|
May 21
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
2,000
-2.35%
|
$122,000
$61.61 P/Share
|
|
May 20
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
12,855
-1.72%
|
$784,155
$61.81 P/Share
|
|
May 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,836
-0.78%
|
$361,832
$62.09 P/Share
|
|
May 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
16,459
-2.14%
|
$1,036,917
$63.84 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 366K shares |
|---|---|
| Exercise of conversion of derivative security | 43.1K shares |
| Payment of exercise price or tax liability | 104K shares |
|---|---|
| Open market or private sale | 1.19M shares |